Your browser doesn't support javascript.
loading
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.
van der Horst, Hilma J; Gelderloos, Anne T; Chamuleau, Martine E D; Breij, Esther C W; Zweegman, Sonja; Nijhof, Inger S; Overdijk, Marije B; Mutis, Tuna.
Afiliação
  • van der Horst HJ; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and.
  • Gelderloos AT; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and.
  • Chamuleau MED; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and.
  • Breij ECW; Genmab, Utrecht, The Netherlands.
  • Zweegman S; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and.
  • Nijhof IS; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and.
  • Overdijk MB; Genmab, Utrecht, The Netherlands.
  • Mutis T; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and.
Blood Adv ; 5(8): 2165-2172, 2021 04 27.
Article em En | MEDLINE | ID: mdl-33885752

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo / Antineoplásicos Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo / Antineoplásicos Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2021 Tipo de documento: Article